Topical Acne and Rosacea Agents

NOTICE

This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242.

BENEFIT APPLICATION

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

DESCRIPTION

The intent of the prior authorization (PA) criteria for Topical Acne and Rosacea Agents is to ensure appropriate selection of patients for treatment according to product labeling and/or clinical studies and/or guidelines, encourage the use of more cost-effective generic and over-the-counter (OTC) agents prior to the use of a generic or brand name combination agents, a brand name agent, or a more costly generic when using for the treatment of acne or rosacea, and discourage the use of topical retinoid agents for cosmetic purposes while maintaining patient access for the treatment of medical skin conditions. For the single agent tretinoin products, prior authorization is not required for members under 36 years of age.

Renova and Refissa are indicated as adjunctive agents for use in the mitigation of fine facial wrinkles in patients who use comprehensive skin care and sunlight avoidance programs. Since the treatment of these indications is considered cosmetic and not a covered benefit, these products are not included in the criteria for coverage.

FDA-Approved Indications

Acanya, Benzaclin, Duac, Neuac, Onexton, and generic equivalents are combination topical products containing benzoyl peroxide and clindamycin indicated for the treatment of acne vulgaris in patients 12 years and older.

Differin, Plixda, and generic equivalents are topical retinoids indicated for the treatment of acne vulgaris in patients 12 years and older.

Epiduo and Epiduo Forte are combination topical products containing benzoyl peroxide and adapalene indicated for the treatment of acne vulgaris in patients 12 years and older.
Evoclin and generic equivalents are a topical foam formulation of clindamycin indicated for the treatment of acne vulgaris in patients 12 years and older.

Aczone is a topical anti-infective agent indicated for the treatment of acne vulgaris in patients 12 years and older.

Amzeeq is a topical anti-infective agent indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years and older

Fabior is a topical foam formulation of tazarotene indicated for the treatment of acne vulgaris in patients 12 years and older.

Azelex is a topical cream formulation of azelaic acid indicated for the treatment of mild to moderate inflammatory acne vulgaris.

Finacea 15% foam is a topical gel formulation of azelaic acid indicated for the treatment of inflammatory papules and pustules of mild to moderate rosacea.

Mirvaso is a topical gel indicated for the topical treatment of persistent (non-transient) facial erythema of rosacea in adults 18 years of age or older.

Soolantra is a topical cream indicated for the treatment of inflammatory lesions of rosacea.

Rhofade is a topical cream indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.

Noritate 1% cream is a topical cream indicated for the topical treatment of inflammatory lesions and erythema of rosacea in adults.


Veltin and Ziana are indicated for the topical treatment of acne vulgaris in patients 12 years or older.

Altreno (tretinoin) 0.05% lotion is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

**POLICY**

Criteria for Initial Approval

I. Acanya, Benzaclin, Duac, Neuac, Onexton, and generic equivalents may be considered medically necessary for the topical treatment of acne vulgaris in patients 12 years and older when the following criteria are met:
   • Patient must experience an inadequate response, adverse event, intolerance, or contraindication to the combined use of the individual topical ingredients, clindamycin and over-the-counter benzoyl peroxide. Treatment failure cannot be caused by a lack of compliance to therapy or the unwillingness to take the two ingredients separately.

Approval will be for 12 months
II. Differin, Plixda and generic equivalents may be considered medically necessary for the topical treatment of acne vulgaris in patients 12 years and older when the following criteria are met:
   • Patient must experience an inadequate response, adverse event, intolerance, or contraindication to over-the-counter or prescription Differin 0.1% (adapalene) gel alone or in combination with over-the-counter benzoyl peroxide unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).

   Approval will be for 12 months

III. Epiduo Forte Gel 0.3-2.5% may be considered medically necessary for the topical treatment of acne vulgaris in patients 12 years and older when ALL of the following criteria are met:
   • Patient must experience an inadequate response, adverse event, intolerance, or contraindication to the combined use of the individual topical ingredients, over-the-counter or prescription Differin 0.1% (adapalene) and over-the-counter benzoyl peroxide unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs). Treatment failure cannot be caused by a lack of compliance to therapy or the unwillingness to take the two ingredients separately.
   • Patient must experience an inadequate response, adverse event, intolerance, or contraindication to the combined use of the individual topical ingredients, prescription Differin 0.3% (adapalene) and over-the-counter benzoyl peroxide. Treatment failure cannot be caused by a lack of compliance to therapy or the unwillingness to take the two ingredients separately.

   Approval will be for 12 months

IV. Epiduo 0.1-2.5% may be considered medically necessary for the topical treatment of acne vulgaris in patients 9 years and older when ALL of the following criteria are met:
   • Patient must experience an inadequate response, adverse event, intolerance, or contraindication to the combined use of the individual topical ingredients, over-the-counter or prescription Differin 0.1% (adapalene) and over-the-counter benzoyl peroxide unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs). Treatment failure cannot be caused by a lack of compliance to therapy or the unwillingness to take the two ingredients separately.

   Approval will be for 12 months

V. Evoclin (clindamycin 1% foam) and generic equivalents may be considered medically necessary for the topical treatment of acne vulgaris and folliculitis in patients 12 years and older when the following criteria are met:
   • Patient must experience an inadequate response, adverse event, intolerance, or contraindication to another topical generic clindamycin formulation (i.e., gel, lotion, and solution). Treatment failure cannot be caused by a lack of compliance to therapy or the unwillingness to take the other formulations.

   Approval will be for 12 months

VI. Brand and generic Aczone 5% may be considered medically necessary for the topical treatment of acne vulgaris in patients 12 years and older when ALL of the following criteria are met:
   • Patient must experience an inadequate response, adverse event, intolerance, or contraindication to topical clindamycin in combination with over-the-counter benzoyl peroxide unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).

Wellmark Blue Cross and Blue Shield is an independent licensee of the Blue Cross and Blue Shield Association. © 2020 Wellmark, Inc.
- Patient must experience an inadequate response, adverse event, intolerance, or contraindication to over-the-counter or prescription Differin 0.1% (adapalene) alone or in combination with over-the-counter benzoyl peroxide unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer's patient assistance programs).

**Approval will be for 12 months**

VII. **Aczone 7.5%** may be considered medically necessary for the topical treatment of acne vulgaris in patients 12 years and older when ALL of the following criteria are met:
- Patient must experience an inadequate response, adverse event, intolerance, or contraindication to topical clindamycin in combination with over-the-counter benzoyl peroxide unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).
- Patient must experience an inadequate response, adverse event, intolerance, or contraindication to over-the-counter or prescription Differin 0.1% (adapalene) alone or in combination with over-the-counter benzoyl peroxide unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).
- Patient must experience an inadequate response, adverse event, intolerance, or contraindication to generic Dapsone 5% gel unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).

**Approval will be for 12 months**

VIII. **Fabior** may be considered medically necessary for the topical treatment of acne vulgaris in patients 12 years and older when the following criteria are met:
- Patient must experience an inadequate response, adverse event, intolerance, or contraindication to generic tazarotene 0.1% cream.

**Approval will be for 12 months**

IX. **Aklief** may be considered medically necessary for the topical treatment of acne vulgaris in patients 12 years and older when ALL of the following criteria are met:
- Patient must experience an inadequate response, adverse event, intolerance, or contraindication to topical clindamycin in combination with over-the-counter benzoyl peroxide unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).
- Patient must experience an inadequate response, adverse event, intolerance, or contraindication to over-the-counter or prescription Differin 0.1% (adapalene) alone or in combination with over-the-counter benzoyl peroxide unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).

**Approval will be for 12 months**

X. **Amzeeq** may be considered medically necessary for the topical treatment of non-nodular moderate to severe acne vulgaris in patients 9 years and older when ALL of the following criteria are met:
- Patient must experience an inadequate response, adverse event, intolerance, or contraindication to topical clindamycin in combination with over-the-counter benzoyl peroxide unless the patient is
currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).

- Patient must experience an inadequate response, adverse event, intolerance, or contraindication to over-the-counter or prescription Differin 0.1% (adapalene) alone or in combination with over-the-counter benzoyl peroxide unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).

Approval will be for 6 months

XI. Azelex may be considered medically necessary in patients 12 years and older when the following criteria are met:

- The patient has a diagnosis of acne vulgaris AND has experienced an inadequate response, adverse event, intolerance, or contraindication to ALL of the following agents, unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs):
  - Topical clindamycin in combination with over-the-counter benzoyl peroxide
  - Over-the-counter or prescription Differin 0.1% (adapalene) alone or in combination with over-the-counter benzoyl peroxide

OR

- The patient has a diagnosis of rosacea AND has experienced an inadequate response, adverse event, intolerance, or contraindication to ALL of the following agents, unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs):
  - Topical metronidazole
  - Oral doxycycline
  - Brand or generic Finacea (azelaic acid) 15% gel

Approval will be for 12 months

XII. Treatment with topical retinoid acne products, Atralin, Altreno 0.05% lotion, Avita, Retin-A, Retin-A Micro, Tretin-X gel and Tretin-X cream, including generics, may be considered medically necessary for patients who have been diagnosed with a medical skin condition for which treatment with a topical retinoid is medically indicated.

Approval will be for 12 months

*The use of topical retinoid acne products for the treatment of cosmetic conditions is not covered.

XIII. Veltin and Ziana, including generics, may be considered medically necessary for the treatment of acne vulgaris when the following criteria are met:

- Patient must experience an inadequate response, adverse event, intolerance, or contraindication to the combined use of the individual active ingredients in the requested medication, topical tretinoin and topical clindamycin. Treatment failure cannot be caused by a lack of compliance to therapy or the unwillingness to take the other formulations.

Approval will be for 12 months

XIV. Finacea 15% foam may be considered medically necessary for the topical treatment of rosacea in patients 18 years and older when the following criteria are met:

- Patient has a diagnosis of rosacea
• Patient must experience an inadequate response, adverse event, intolerance, or contraindication to topical metronidazole unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).
• Patient must experience an inadequate response, adverse event, intolerance, or contraindication to brand or generic Finacea (azelaic acid) 15% gel
• Patient must experience an inadequate response, adverse event, intolerance, or contraindication to oral doxycycline unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).

Approval will be for 12 months

XV. Brand and generic Soolantra (ivermectin topical) may be considered medically necessary for the topical treatment of rosacea in patients 18 years and older when the following criteria are met:
• Patient has a diagnosis of rosacea
• Patient must experience an inadequate response, adverse event, intolerance, or contraindication to topical metronidazole unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).
• Patient must experience an inadequate response, adverse event, intolerance, or contraindication to brand or generic Finacea (azelaic acid) 15% gel unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).
• Patient must experience an inadequate response, adverse event, intolerance, or contraindication to oral doxycycline unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).

Approval will be for 12 months

XVI. Mirvaso and Rhofade may be considered medically necessary for the topical treatment of rosacea in patients 18 years and older when the following criteria are met:
• Patient has a diagnosis of persistent facial erythema associated with rosacea

Approval will be for 12 months

XVII. Noritate 1% cream may be considered medically necessary for the topical treatment of rosacea in patients 18 years and older when the following criteria are met:
• Patient has a diagnosis of rosacea
• Patient must experience an inadequate response, adverse event, intolerance, or contraindication to topical metronidazole 1% gel AND topical metronidazole 0.75% cream
• Patient must experience an inadequate response, adverse event, intolerance, or contraindication to brand or generic Finacea (azelaic acid) 15% gel unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).
• Patient must experience an inadequate response, adverse event, intolerance, or contraindication to oral doxycycline unless the patient is currently receiving a positive therapeutic outcome on the requested medication through health insurance (excludes obtainment as samples or via manufacturer’s patient assistance programs).
Approval will be for 12 months

XVIII. The aforementioned drugs are considered not medically necessary for patients who do not meet the criteria set forth above.

Continuation of Therapy
All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria above and a documentation of positive clinical response to the requested therapy.

Dosing and Administration
Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

PROCEDURES AND BILLING CODES

To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or ICD diagnostic codes.

• Code(s), if applicable

REFERENCES

• Differin 0.3% [Prescribing Information] Forth Worth, TX: Galderma Laboratories, L.P.; February 2012.
• Epiduo Forte [Prescribing Information] Fort Worth, TX: Galderma Laboratories; July 2015.
• Azelex [Prescribing Information]. Irvine, CA: Allergan; September 2015.
• Soolantra [Prescribing Information]. Fort Worth, TX: Galderma Laboratries, LP; April 2018.
• Mirvaso [Prescribing Information]. Fort Worth, TX: Galderma Labs; July 2016.
• Aklief (trifarotene) [prescribing information]. Fort Worth, TX: Galderma Laboratories LP: October 2019.
• Noritrate (metronidazole) 1% cream [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; June 2019.
• Amzeeq (minocycline) [prescribing information]. Bridgewater, NJ: Foamix Pharmaceuticals Inc; October 2019.

POLICY HISTORY

Policy #: 05.01.114
Policy Creation: July 2016
Reviewed: October 2019
Revised: December 2019
Current Effective Date: January 31, 2020